NCT01993875 - Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Chronic Idiopathic Constipation

Interventions

DRUG

Lubiprostone

Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)

DRUG

Placebo

Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)

Trial Locations (11)

Raleigh

DeLand

Orlando

Hollywood

South Miami

Anniston

West Bend

Overland Park

Salt Lake City

Anaheim

Marlton